1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Alzheimer's Disease - Pipeline Review, H1 2015

Alzheimer's Disease - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 1197 pages

Alzheimer's Disease - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Alzheimer's Disease - Pipeline Review, H1 2015’, provides an overview of the Alzheimer's Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Alzheimer's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Alzheimer's Disease - Pipeline Review, H1 2015
Table of Contents
Table of Contents 2
Introduction 11
Alzheimer's Disease Overview 12
Therapeutics Development 13
Alzheimer's Disease - Therapeutics under Development by Companies 15
Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes 33
Alzheimer's Disease - Pipeline Products Glance 41
Alzheimer's Disease - Products under Development by Companies 45
Alzheimer's Disease - Products under Investigation by Universities/Institutes 73
Alzheimer's Disease - Companies Involved in Therapeutics Development 83
Alzheimer's Disease - Therapeutics Assessment 285
Drug Profiles 306
Alzheimer's Disease - Recent Pipeline Updates 968
Alzheimer's Disease - Dormant Projects 1089
Alzheimer's Disease - Discontinued Products 1122
Alzheimer's Disease - Product Development Milestones 1132
Appendix 1138

List of Tables

Number of Products under Development for Alzheimer's Disease, H1 2015 71
Number of Products under Development for Alzheimer's Disease - Comparative Analysis, H1 2015 72
Number of Products under Development by Companies, H1 2015 74
Number of Products under Development by Companies, H1 2015 (Contd..1) 75
Number of Products under Development by Companies, H1 2015 (Contd..2) 76
Number of Products under Development by Companies, H1 2015 (Contd..3) 77
Number of Products under Development by Companies, H1 2015 (Contd..4) 78
Number of Products under Development by Companies, H1 2015 (Contd..5) 79
Number of Products under Development by Companies, H1 2015 (Contd..6) 80
Number of Products under Development by Companies, H1 2015 (Contd..7) 81
Number of Products under Development by Companies, H1 2015 (Contd..8) 82
Number of Products under Development by Companies, H1 2015 (Contd..9) 83
Number of Products under Development by Companies, H1 2015 (Contd..10) 84
Number of Products under Development by Companies, H1 2015 (Contd..11) 85
Number of Products under Development by Companies, H1 2015 (Contd..12) 86
Number of Products under Development by Companies, H1 2015 (Contd..13) 87
Number of Products under Development by Companies, H1 2015 (Contd..14) 88
Number of Products under Development by Companies, H1 2015 (Contd..15) 89
Number of Products under Development by Companies, H1 2015 (Contd..16) 90
Number of Products under Investigation by Universities/Institutes, H1 2015 92
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 93
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 94
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 95
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 96
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 97
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..6) 98
Comparative Analysis by Late Stage Development, H1 2015 99
Comparative Analysis by Clinical Stage Development, H1 2015 100
Comparative Analysis by Early Stage Development, H1 2015 101
Comparative Analysis by Unknown Stage Development, H1 2015 102
Products under Development by Companies, H1 2015 103
Products under Development by Companies, H1 2015 (Contd..1) 104
Products under Development by Companies, H1 2015 (Contd..2) 105
Products under Development by Companies, H1 2015 (Contd..3) 106
Products under Development by Companies, H1 2015 (Contd..4) 107
Products under Development by Companies, H1 2015 (Contd..5) 108
Products under Development by Companies, H1 2015 (Contd..6) 109
Products under Development by Companies, H1 2015 (Contd..7) 110
Products under Development by Companies, H1 2015 (Contd..8) 111
Products under Development by Companies, H1 2015 (Contd..9) 112
Products under Development by Companies, H1 2015 (Contd..10) 113
Products under Development by Companies, H1 2015 (Contd..11) 114
Products under Development by Companies, H1 2015 (Contd..12) 115
Products under Development by Companies, H1 2015 (Contd..13) 116
Products under Development by Companies, H1 2015 (Contd..14) 117
Products under Development by Companies, H1 2015 (Contd..15) 118
Products under Development by Companies, H1 2015 (Contd..16) 119
Products under Development by Companies, H1 2015 (Contd..17) 120
Products under Development by Companies, H1 2015 (Contd..18) 121
Products under Development by Companies, H1 2015 (Contd..19) 122
Products under Development by Companies, H1 2015 (Contd..20) 123
Products under Development by Companies, H1 2015 (Contd..21) 124
Products under Development by Companies, H1 2015 (Contd..22) 125
Products under Development by Companies, H1 2015 (Contd..23) 126
Products under Development by Companies, H1 2015 (Contd..24) 127
Products under Development by Companies, H1 2015 (Contd..25) 128
Products under Development by Companies, H1 2015 (Contd..26) 129
Products under Development by Companies, H1 2015 (Contd..27) 130
Products under Investigation by Universities/Institutes, H1 2015 131
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 132
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 133
Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 134
Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 135
Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 136
Products under Investigation by Universities/Institutes, H1 2015 (Contd..6) 137
Products under Investigation by Universities/Institutes, H1 2015 (Contd..7) 138
Products under Investigation by Universities/Institutes, H1 2015 (Contd..8) 139
Products under Investigation by Universities/Institutes, H1 2015 (Contd..9) 140
Alzheimer's Disease - Pipeline by AB Science, H1 2015 141
Alzheimer's Disease - Pipeline by AbbVie Inc., H1 2015 142
Alzheimer's Disease - Pipeline by AC Immune SA, H1 2015 143
Alzheimer's Disease - Pipeline by Acadia Pharmaceuticals Inc., H1 2015 144
Alzheimer's Disease - Pipeline by Acelot, Inc., H1 2015 145
Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals, Inc., H1 2015 146
Alzheimer's Disease - Pipeline by Adamas Pharmaceuticals, Inc., H1 2015 147
Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H1 2015 148
Alzheimer's Disease - Pipeline by AFFiRiS AG, H1 2015 149
Alzheimer's Disease - Pipeline by Alector LLC, H1 2015 150
Alzheimer's Disease - Pipeline by ALSP, Inc., H1 2015 151
Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, H1 2015 152
Alzheimer's Disease - Pipeline by Alzinova AB, H1 2015 153
Alzheimer's Disease - Pipeline by AlzProtect SAS, H1 2015 154
Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2015 155
Alzheimer's Disease - Pipeline by Amgen Inc., H1 2015 156
Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp., H1 2015 157
Alzheimer's Disease - Pipeline by Angita B.V., H1 2015 158
Alzheimer's Disease - Pipeline by Apodemus AB, H1 2015 159
Alzheimer's Disease - Pipeline by Araclon Biotech, S.L., H1 2015 160
Alzheimer's Disease - Pipeline by Archer Pharmaceuticals, Inc., H1 2015 161
Alzheimer's Disease - Pipeline by ArmaGen Technologies, Inc., H1 2015 162
Alzheimer's Disease - Pipeline by Artery Therapeutics, Inc., H1 2015 163
Alzheimer's Disease - Pipeline by Astellas Pharma Inc., H1 2015 164
Alzheimer's Disease - Pipeline by AstraZeneca PLC, H1 2015 165
Alzheimer's Disease - Pipeline by Ausio Pharmaceuticals, LLC, H1 2015 166
Alzheimer's Disease - Pipeline by Avergen Ltd, H1 2015 167
Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2015 168
Alzheimer's Disease - Pipeline by Axerion Therapeutics, Inc., H1 2015 169
Alzheimer's Disease - Pipeline by Axon Neuroscience SE, H1 2015 170
Alzheimer's Disease - Pipeline by Axxam SpA, H1 2015 171
Alzheimer's Disease - Pipeline by Azevan Pharmaceuticals, Inc., H1 2015 172
Alzheimer's Disease - Pipeline by BioArctic Neuroscience AB, H1 2015 173
Alzheimer's Disease - Pipeline by biOasis Technologies Inc., H1 2015 174
Alzheimer's Disease - Pipeline by Biogen Idec Inc., H1 2015 175
Alzheimer's Disease - Pipeline by Biomar Microbial Technologies, H1 2015 176
Alzheimer's Disease - Pipeline by Bionature E.A. Ltd., H1 2015 177
Alzheimer's Disease - Pipeline by Biotie Therapies Corp., H1 2015 178
Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H1 2015 179
Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Company, H1 2015 180
Alzheimer's Disease - Pipeline by Bsim2, H1 2015 181
Alzheimer's Disease - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2015 182
Alzheimer's Disease - Pipeline by Cardax Pharmaceuticals, Inc., H1 2015 183
Alzheimer's Disease - Pipeline by Celon Pharma Sp. z o.o., H1 2015 184
Alzheimer's Disease - Pipeline by CHA Bio and Diostech Co., Ltd., H1 2015 185
Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H1 2015 186
Alzheimer's Disease - Pipeline by Clera Inc., H1 2015 187
Alzheimer's Disease - Pipeline by Cognition Therapeutics, Inc., H1 2015 188
Alzheimer's Disease - Pipeline by Cognosci, Inc., H1 2015 189
Alzheimer's Disease - Pipeline by CoLucid Pharmaceuticals, Inc., H1 2015 190
Alzheimer's Disease - Pipeline by CoMentis, Inc., H1 2015 191
Alzheimer's Disease - Pipeline by Cortica Neurosciences, Inc., H1 2015 192
Alzheimer's Disease - Pipeline by Critical Outcome Technologies Inc., H1 2015 193
Alzheimer's Disease - Pipeline by CrystalGenomics, Inc., H1 2015 194
Alzheimer's Disease - Pipeline by D-Pharm Ltd., H1 2015 195
Alzheimer's Disease - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 196
Alzheimer's Disease - Pipeline by Delenex Therapeutics AG, H1 2015 197
Alzheimer's Disease - Pipeline by DermaXon, LLC, H1 2015 198
Alzheimer's Disease - Pipeline by Domain Therapeutics SA, H1 2015 199
Alzheimer's Disease - Pipeline by Echo Pharmaceuticals B.V., H1 2015 200
Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H1 2015 201
Alzheimer's Disease - Pipeline by Eli Lilly and Company, H1 2015 202

List of Figures
Number of Products under Development for Alzheimer's Disease, H1 2015 71
Number of Products under Development for Alzheimer's Disease - Comparative Analysis, H1 2015 72
Number of Products under Development by Companies, H1 2015 73
Number of Products under Investigation by Universities/Institutes, H1 2015 91
Comparative Analysis by Clinical Stage Development, H1 2015 100
Comparative Analysis by Early Stage Products, H1 2015 101
Assessment by Monotherapy Products, H1 2015 343
Assessment by Combination Products, H1 2015 344
Number of Products by Top 10 Targets, H1 2015 345
Number of Products by Stage and Top 10 Targets, H1 2015 345
Number of Products by Top 10 Mechanism of Actions, H1 2015 353
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 353
Number of Products by Top 10 Routes of Administration, H1 2015 360
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 360
Number of Products by Top 10 Molecule Types, H1 2015 362
Number of Products by Stage and Top 10 Molecule Types, H1 2015 362

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

DelveInsight’s Alzheimer’s disease (AD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Alzheimer’s disease ...

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Amyotrophic lateral sclerosis (ALS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of ...

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

Global Multi Infarct Dementia Market Insights, Opportunity Analysis, Market Shares and Forecast, 2016 - 2022

  • $ 3900
  • Industry report
  • November 2016
  • by Occams

"Global Multi Infarct Dementia Market Research Report 2016" by OBRC, is an extensive study on present state of the Multi Infarct Dementia Market. The global multi-infarct dementia is estimated to reach ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.